<p>In the course of screening for anti-enterococcal antibiotics from microbial resources, a new tirandamycin congener (<b>1</b>), together with four known tirandamycins (<b>2</b> to <b>5</b>), were isolated from <i>Streptomyces tirandamycinicus</i> TMPU-20A040. The structures of these tirandamycins were elucidated using NMR and MS analyses; <b>1</b> was identified as 12-carboxy tirandamycin A and <b>2</b> to <b>5</b> as known tirandamycins A (<b>2</b>), B (<b>3</b>), E (<b>4</b>), and J (<b>5</b>). Compounds <b>1</b> to <b>3</b> exhibited selective anti-Enterococci activity, including vancomycin-resistant strains, with MIC in the range of 1.0 to 64 µg ml<sup>–1</sup> in the microdilution method. <b>2</b> and <b>3</b> exerted weak therapeutic effects in the in vivo-mimic silkworm <i>Enterococcus faecalis</i> infection model with ED<sub>50</sub> values of 150 and 75 µg larva<sup>–1</sup> g<sup>–1</sup>, respectively, indicating that the in vivo activities of <b>2</b> and <b>3</b> were lower than their in vitro activities. Further investigations into the causes of the decreased in vivo activities of <b>2</b> and <b>3</b> suggested the low plasma protein binding ratio of these compounds, but revealed short half-lives of 6.3 and 16 min, respectively, in the silkworm hemolymph.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Evaluation of tirandamycins with selective activity against Enterococci in the silkworm infection model

  • Akiho Yagi,
  • Taku Sato,
  • Chihiro Kano,
  • Taeko Igari,
  • Natsuki Oshima,
  • Satoshi Ohte,
  • Taichi Ohshiro,
  • Ryuji Uchida

摘要

In the course of screening for anti-enterococcal antibiotics from microbial resources, a new tirandamycin congener (1), together with four known tirandamycins (2 to 5), were isolated from Streptomyces tirandamycinicus TMPU-20A040. The structures of these tirandamycins were elucidated using NMR and MS analyses; 1 was identified as 12-carboxy tirandamycin A and 2 to 5 as known tirandamycins A (2), B (3), E (4), and J (5). Compounds 1 to 3 exhibited selective anti-Enterococci activity, including vancomycin-resistant strains, with MIC in the range of 1.0 to 64 µg ml–1 in the microdilution method. 2 and 3 exerted weak therapeutic effects in the in vivo-mimic silkworm Enterococcus faecalis infection model with ED50 values of 150 and 75 µg larva–1 g–1, respectively, indicating that the in vivo activities of 2 and 3 were lower than their in vitro activities. Further investigations into the causes of the decreased in vivo activities of 2 and 3 suggested the low plasma protein binding ratio of these compounds, but revealed short half-lives of 6.3 and 16 min, respectively, in the silkworm hemolymph.